tuberculosis, but oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC), a DAMP released by dying cells, and the cyclic GMP-AMP synthase/stimulator ... mortality in those who ...

A couple of months after getting FDA approval for Sarclisa (isatuximab) as a third-line myeloma treatment in combination with Bristol-Myers Squibb’s Pomalyst (pomalidomide) and dexamethasone ...

plus dexamethasone or Amgen's Kyprolis (carfilzomib) plus dexamethasone. It is mounting a challenge to Johnson & Johnson's market-leading CD38 drug Darzalex (daratumumab), which was originally ...

AMP price predictions hint at a maximum price of $0.0121 by the end of 2025 while maintaining an average price of $0.0101. In 2028, the price of AMP will range between $0.0283 and $0.0323, with an ...

After hours: February 4 at 6:28:44 PM EST ...

Provides financial advice and superannuation, retirement income, banking and investment products across a portfolio of businesses along with corporate superannuation products and services for ...